Meridian Bioscience Inc

Meridian Bioscience — Q3 FY2021 Earnings Presentation

15 slides from Meridian Bioscience's earnings presentation, Aug 6, 2021

  1. Slide 1: FY2021 Q3 Results

    FY2021 Q3 Results August 6, 2021 Exhibit 99.2

  2. Slide 2: Forward-Looking Statements

    The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A

  3. Slide 3: Non-GAAP Financial Measures

    Certain financial measures presented in this presentation, such as operating expenses, operating income, operating margin, net earnings and net earnings per diluted share, each on an adjusted basis, excluding as applicable the effects of acquisition-related costs, changes in fair value of acquisitio

  4. Slide 4: Q3 FY2021 Business Highlights

    Re-Submitted EUA for Revogene ® SARS-CoV-2 assay Launched Lyo-Ready master mixes for LAMP technology Launched Air-Dryable™ master mixes for saliva and plant-based samples Completed remediation of quality system at Billerica manufacturing site – October 2017 FDA warning letter closed Q3 FY2021 Busine

  5. Slide 5: FY2021 Third Quarter Earnings Summary

    FY2021 Third Quarter Earnings Summary ($000’s except Per Share Amounts) Adjusted (Non-GAAP) FY2021 FY2020 Change Net revenues $63,511 $84,797 -25% Gross margin % 58% 66% -8 pts Operating expenses(1) Ratio $24,256 38% $25,574 30% -5% +8 pts Operating income Margin % $12,855 20% $30,409 36% -58% -16 p

  6. Slide 6: FY2021 Third Quarter Operating Segment Highlights

    FY2021 Third Quarter Operating Segment Highlights ($000’s) Diagnostics segment (Adjusted Non-GAAP) FY2021 FY2020 Change Net revenues $31,189 $21,598 +44% Operating income / (loss) Margin % ($753) NMF ($6,170) NMF NMF NMF Diagnostics segment revenues by: Technology: Molecular assays $4,383 $3,182 +38

  7. Slide 7: FY2021 Fiscal Year Guidance

    FY2021 Fiscal Year Guidance Meridian Bioscience Diagnostics Life Science Prior Guidance (5/7/2021) Updated FY2021 Guidance Meridian Bioscience Consolidated net revenues: $308 to $314 Million Adjusted operating margin: 30% to 31% Adjusted net earnings per share*: $1.61 to $1.67 Diagnostics Net revenu

  8. Slide 8: Diagnostics R&D Pipeline (as of 6/30/2021)

    Diagnostics R&D Pipeline (as of 6/30/2021) Breath Immunoassay Molecular Blood Chemistry Feasibility Development Clinicals FDA Liver MBT PMA C. difficile Shiga Toxin Streptococcus pneumoniae / Legionella RI Panel GI Panel COVID-19 EUA PediaStat Analyzer Lead Expected FY21 FDA Submissions Campylobacte

  9. Slide 9: H. pylori Opportunity

    H. pylori Opportunity ~~

  10. Slide 10: H. pylori infection

    H. pylori infection Lifelong infection unless treated Causes >90% duodenal ulcers Causes >85% gastric ulcers Infected persons have 2- to 6-fold increase risk for gastric cancers and/or mucosal-associated lymphoid type lymphoma (MALT) Classified as a carcinogen by WHO H. pylori Infection Prevalence 2

  11. Slide 11: Diagnostic Test Comparison

    Features Endoscopy + RUT/Histology/ Culture Serology Urea Breath (UBT) Stool Antigen (HpSA) Relative invasiveness Severe Low Non Non Technical skill level Physician and Pathologist/Lab personnel Lab personnel Nurse or Lab personnel Lab personnel Rapid/Ease of use ü ü ü Detect active infection ü ü ü

  12. Slide 12: Accuracy of H. pylori Detection Methods

    Accuracy of H. pylori Detection Methods Test Method Sensitivity Specificity Endoscopy – Culture 77-95% 95-100% Endoscopy – CLO/Rapid Urease Test 89-95% 90-98% Endoscopy – Staining 80-95% 98-100% Serology 80-95% 79-90% Urea Breath Test 95-100% 90-99% Stool Antigen 91-100% 92-98%

  13. Slide 13: H. pylori Diagnostics: Serology Antibody Testing

    H. pylori Diagnostics: Serology Antibody Testing Serology is NOT clinically recommended by any guidelines; cannot detect active infection. Serology testing is often NOT reimbursed. Serology users tend to “inappropriately” use serology to rule out H. pylori first and then reflex positive serology tes

  14. Slide 14: SS irenemcne

    SS irenemcne

  15. Slide 15: Contact

    Contact: [email protected]

Meridian Bioscience — Q3 FY2021 Earnings Presentation on 6ix